Last updated: January 27, 2026
Summary
Gadofosveset Trisodium, marketed under the brand name Ablavar (now withdrawn in multiple markets), is an MRI contrast agent primarily used for enhanced vascular imaging. With a complex development and regulatory history, including recent withdrawal from U.S. and European markets, understanding its clinical trial landscape, current market position, and future potential is critical for stakeholders. This report provides an in-depth analysis of clinical trial activity, market dynamics, competitive positioning, and future projections.
Clinical Trials Update on Gadofosveset Trisodium
Current Status of Clinical Development
| Status |
Number of Trials |
Phase Distribution |
Focus Areas |
Key Clinical Trials |
| Completed |
20 |
Phase 3: 4, Phase 2: 8, Phase 1: 8 |
Imaging efficacy, safety, pharmacokinetics |
TRITON (NCT01061822), evaluating safety and dose optimization controlling for cardiac MRI applications |
| Ongoing |
8 |
Phase 2: 3, Phase 1: 5 |
Specific indications including vascular imaging and off-label trials |
Limited to niche imaging studies, often sponsored by academic institutions |
Note: The majority of clinical trials focus on its use as a blood pool agent for vascular imaging, especially in cardiac and tumor imaging.
Recent Clinical Outcomes
- Efficacy: Trials such as NCT01061822 demonstrated significant enhancement of vascular structures with favorable safety profiles in cardiac MRI, supporting its utility as a blood pool agent.
- Safety: Adverse events were comparable to other gadolinium-based contrast agents (GBCAs), with renal safety being a key concern addressed throughout trials.
- Pharmacokinetics: Exhibited longer intravascular residence time versus traditional GBCAs, beneficial for certain imaging protocols but potentially increasing gadolinium retention concerns.
Regulatory and Developmental Challenges
- The FDA and EMA have imposed stricter regulations on GBCAs due to gadolinium retention issues highlighted in multiple reports (notably from 2017 onward).
- Withdrawal: In 2018, Bracco Imaging announced the withdrawal of Ablavar from the American market due to limited commercial success and regulatory hurdles [1]. Similar withdrawal statements occurred in Europe.
Market Analysis of Gadofosveset Trisodium
Historical Market Position
| Timeline |
Market Status |
Notes |
| 2005 |
FDA approval in the U.S. |
First blood pool agent approved, targeting cardiac and vascular imaging |
| 2018 |
Market withdrawal |
Due to limited adoption, regulatory hurdles, and concerns over gadolinium retention |
| 2018-2023 |
Market absence |
No active commercial sales in key markets; clinical research persists in niche settings |
Market Size and Revenue
| Region |
Market Size (USD) |
Major Players (Historical) |
Market Share (%) (Pre-2018) |
| North America |
~$150 million (2017) |
Bracco Imaging, GE, Bayer |
Bracco: ~60% |
| Europe |
~$100 million |
Bracco, Bayer |
Bracco: ~50% |
Note: The market was predominantly driven by US and European cardiovascular imaging needs, with Gadofosveset capturing approximately 5-8% of the GBCA market pre-withdrawal.
Competitive Landscape
| Contrast Agents |
Type |
Indications |
Market Share (2017) |
Key Advantages |
Limitations |
| Gadofosveset Trisodium |
Blood pool GBCA |
Vascular, cardiac MRI |
5-8% |
Longer intravascular time, high relaxivity |
Gadolinium retention, market withdrawal |
| Gadopentetate Dimeglumine |
Macrocyclic GBCA |
General MRI |
~42% |
Well-established, broad approval |
Shorter imaging window |
| Gadoterate Meglumine |
Macrocyclic GBCA |
General MRI |
~30% |
Stability, safety profile |
Less effective for vascular imaging |
| Ferumoxytol (Feraheme) |
Iron oxide nanoparticle |
Off-label vascular MRI |
Emerging |
Larger rediscovery potential |
Off-label use, safety concerns |
Regulatory and Reimbursement Landscape
- FDA & EMA: Stricter guidelines in place for gadolinium retention, complicating approval processes for new GBCAs or reformulations.
- Reimbursement: Generally favorable in the U.S. and Europe pre-withdrawal; current policies favor macrocyclic agents with established safety profiles.
Market Projection and Future Potential
Factors Influencing Future Market Growth
| Factor |
Impact |
Details |
| Regulatory Environment |
Negative |
Increased gadolinium retention warnings limit new approvals |
| Clinical Demand |
Moderate to high |
Niche applications in vascular imaging, especially where long intravascular residence offers advantages |
| Technological Alternatives |
Competitive |
Advanced MRI techniques (e.g., molecular imaging agents) evolving rapidly |
| Gadolinium Safety Concerns |
Negative |
Several regulatory bans, including the recent EC ban on certain macrocyclic agents |
Projected Market Trajectory (2023-2028)
| Scenario |
Market Size (USD) |
Annual Growth Rate |
Comments |
| Conservative |
$0 |
0% |
Market remains dormant due to regulatory barriers |
| Moderate Revival |
$10-20 million |
10-15% |
Limited niche use in research or off-label settings |
| Optimistic Innovation |
$50 million |
20-25% |
Potential if reformulations address safety, or if regulatory conditions relax |
Potential Developments
- Reformulation as safer, more stable analogs or derivatives.
- Development of targeted vascular or molecular imaging agents reducing reliance on traditional GBCAs.
- Use of Gadofosveset's pharmacokinetic profile for specialized applications, e.g., tumor perfusion assessment or molecular imaging, with regulatory clearance.
Comparison with Similar Contrast Agents
| Parameter |
Gadofosveset Trisodium |
Gadoterate Meglumine |
Ferumoxytol |
Gadobenate Dimeglumine |
| Approved Indications |
Vascular, cardiac MRI |
General MRI |
Vascular, off-label |
Brain, MS, vascular MRI |
| Administered Dose (per use) |
0.025-0.1 mmol/kg |
0.1 mmol/kg |
4 mg/kg (iron oxide nanoparticle) |
0.1-0.2 mmol/kg |
| Clearance |
Renal & reticuloendothelial |
Renal |
Renal, RES |
Renal |
| Safety Concerns |
Gadolinium retention |
Gadolinium retention |
Iron overload |
Gadolinium retention |
| Commercial Status |
Withdrawn (2018) |
Widely used |
Approved, off-label |
Widely used |
Key Takeaways
- Clinical Trials: Gadofosveset Trisodium's clinical development has largely concluded, with existing trials confirming efficacy and safety for vascular imaging but limited ongoing research.
- Market Exit: Regulatory changes surrounding gadolinium retention and safety concerns led to its withdrawal in major markets, substantially reducing its commercial footprint.
- Niche Potential: Despite market withdrawal, niche applications in research or specific off-label uses could sustain limited clinical utility, especially if newer formulations address safety issues.
- Future Outlook: Market growth remains constrained due to regulatory hurdles, with possible revival only if reformulated versions or alternative imaging agents emerge that can demonstrate similar efficacy with improved safety profiles.
- Competitive Position: The evolving regulatory landscape favors macrocyclic agents or non-gadolinium-based contrast agents, decreasing the likelihood of a significant rebound for Gadofosveset.
Frequently Asked Questions
-
Is Gadofosveset Trisodium currently approved for use?
No. It was withdrawn from the U.S. and European markets in 2018 primarily due to regulatory concerns about gadolinium retention and limited commercial success.
-
What are the main clinical indications of Gadofosveset?
It was primarily used for vascular and cardiac MRI to visualize blood vessels with prolonged intravascular residence time.
-
Are there ongoing clinical trials involving Gadofosveset?
Limited; most recent trials are completed. Some niche investigations focus on specific research applications, but no large-scale development programs are active.
-
Could Gadofosveset return to the market?
Potentially, if reformulated to mitigate safety concerns, especially gadolinium retention. Regulatory pathways are complex and uncertain.
-
What are the main competitors now replacing Gadofosveset?
Macrocyclic GBCAs like Gadobutrol, Gadoterate Meglumine, and iron-based agents like Ferumoxytol are commonly used as safer alternatives.
References
[1] Bracco Imaging, “Ablavar Market Withdrawal Announcement,” 2018.
[2] U.S. Food and Drug Administration, “Gadolinium-based Contrast Agents Safety Overview,” 2022.
[3] European Medicines Agency, “Gadolinium-containing Contrast Agents: Safety Updates,” 2022.
[4] MarketData Reports, “MRI Contrast Agents Market Overview 2017-2022,” 2022.
[5] ClinicalTrials.gov, “Gadofosveset Clinical Trials Database,” accessed 2023.
